Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors (STALLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01462396
Recruitment Status : Unknown
Verified February 2015 by Children's Mercy Hospital Kansas City.
Recruitment status was:  Active, not recruiting
First Posted : October 31, 2011
Last Update Posted : February 5, 2015
University of Kansas
Information provided by (Responsible Party):
Children's Mercy Hospital Kansas City

Brief Summary:
Allogeneic stem cell transplantation has been explored for patients with high risk neuroblastoma. Results have been mixed, with only small series and case reports. Recent reports, however, especially with haploidentical transplantation have been more encouraging. Eradication of neuroblastoma may be mediated by both components of the innate immune system (natural killer cells) and through the adaptive immune system via T-cell cytotoxicity and the development of a humoral response to tumor specific antigens and minor histocompatibility antigens. To overcome restrictions created by unavailability of Human leukocyte antigen (HLA) matched donors, stem cell grafts from haploidentical related donors have been explored. Historically, the use of full haplotype mismatched family member donors has been limited by the development of severe graft-versus-host disease and the high rate of graft failure. Graft failure can now be overcome by increasing immunosuppression and increasing the number of transplanted stem cells. The most effective means of graft versus host disease (GVHD) prophylaxis is T cell depletion of the donor marrow. A 3-4 log depletion will reduce the risk of developing significant GVHD to less than 10%. Methods to mobilize stem cells from the bone marrow into the peripheral blood and collect these stem cells by apheresis now increase the availability of stem cells by a magnitude. Selection devices have been developed that will prepare extremely pure populations of these CD34 cells with upwards of 5 logs depletion of contaminating T cells. The CliniMACS CD34 Reagent System is a medical device designed to select CD34+ hematopoietic cells from heterogeneous hematologic cell populations. The investigators intend to provide mismatched related hematopoietic stem cell transplantation to up to 10 patients with relapsed refractory neuroblastoma. Harnessing the potential for innate and adaptive immune responses through allogeneic Hematopoietic stem cell transplantation (HSCT) may provide cure for some patients with this tumor.

Condition or disease Intervention/treatment Phase
Neuroblastoma Device: CD34+ cells selected with the Miltenyi Clinimacs machine Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using Major Histocompatibility Complex (MHC) Mismatched Related Donors and Sub-Myeloablative Regimen
Study Start Date : October 2011
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma
U.S. FDA Resources

Intervention Details:
    Device: CD34+ cells selected with the Miltenyi Clinimacs machine
    Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device

Primary Outcome Measures :
  1. The immediate safety of a fludarabine based reduced intensity conditioning regimen and CD34+ stem cell selected mis-matched, related, allogeneic transplant will be assess in patients with relapsed/refractory neuroblastoma [ Time Frame: 6 weeks ]
    Monitoring of mortality, toxicity (NCI Common Criteria), acute and chronic graft versus host disease, engraftment rate will contribute to safety assessment

Secondary Outcome Measures :
  1. Infusional and long term safety and persistence of tumor redirected, genetically modified, donor derived, allogeneic multi-virus specific cytotoxic T-cells (tV-CTL) after allogeneic hematopoietic stem cell transplant in patients with neuroblastoma [ Time Frame: 4-8 weeks post transplant ]
    Tumor evaluation will occur 4-8 weeks after transplant

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Months to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 6 months - <18 years
  • Measurable tumor by routine imaging or bone marrow biopsy
  • Patient must have an 3/6, 4/6, or 5/6 human leukocyte antigen (HLA)-mismatched related donor who is Epstein-Barr virus (EBV) seropositive
  • Karnofsky score 60% or greater if 10yrs old or older, Lansky score 60% or greater if under 10yrs old
  • Pulse ox >90% on room air
  • Recovered from toxic effects of prior chemotherapy
  • Patient must not be pregnant
  • Patient must be HIV negative
  • Patient or responsible person must be able to understand and sign an informed consent
  • Available donor without contraindication for stem cell collection

Exclusion Criteria:

  • Pregnant and lactating women.
  • Human immunodeficiency virus (HIV) positive patient.
  • Uncontrolled intercurrent infection.
  • Renal failure (Creatine > 1.5 or Creatinine Clearance < 40 ml/min/1.73m2)
  • Active hepatitis or cirrhosis with liver test values greater than 3 times normal
  • NOTE: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigator's discretion, after review by the Children's Mercy Hospital ethics board
  • Donor Inclusion/Exclusion Criteria
  • Donor must be in good health based on review of systems and results of physical examination, and routine testing per standards of good medical care.
  • Female donors of childbearing age must have a negative pregnancy test and must not be lactating
  • EBv seropositive
  • Donor stem cells should be human leukocyte antigen (HLA) typed using molecular methods. See section 6.1.3 for HLA matching requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01462396

United States, Missouri
Children's Mercy Hospital
Kanas City, Missouri, United States, 64108
Sponsors and Collaborators
Children's Mercy Hospital Kansas City
University of Kansas

Additional Information:
Responsible Party: Children's Mercy Hospital Kansas City Identifier: NCT01462396     History of Changes
Other Study ID Numbers: STALLO
First Posted: October 31, 2011    Key Record Dates
Last Update Posted: February 5, 2015
Last Verified: February 2015

Keywords provided by Children's Mercy Hospital Kansas City:

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue